Zumenon

How to order Zumenon

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Zumenon on Prescriptsy

Zumenon is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Zumenon is a brand of estradiol (17-beta-estradiol) oral tablets, available as 1 mg and 2 mg strengths, used as hormone replacement therapy (HRT) for the relief of oestrogen deficiency symptoms associated with menopause.

These symptoms include vasomotor symptoms (hot flushes, night sweats), urogenital atrophy (vaginal dryness, dyspareunia, urinary symptoms), mood disturbance, sleep disruption, and joint pain.

Zumenon provides systemic oestrogen replacement and is used in women with an intact uterus (combined with a progestogen for endometrial protection) or in women who have had a hysterectomy (as oestrogen-only therapy).

It is a prescription-only medicine (POM) in the United Kingdom.

Menopause, defined as the permanent cessation of menstruation resulting from loss of ovarian follicular activity, occurs at a mean age of 51 years in the UK.

Perimenopause (the transition to menopause) typically begins several years earlier, as ovarian oestrogen production declines and menstrual cycles become irregular.

Approximately 75 to 80% of menopausal women experience vasomotor symptoms, with 25% reporting severe symptoms that significantly affect quality of life, work productivity, relationships, and mental health.

HRT remains the most effective treatment for menopausal symptoms, endorsed by NICE guideline NG23 as the first-line pharmacological option.

This page provides a comprehensive clinical guide to Zumenon, covering how it works, dosage, side effects, safety information including thrombotic and cancer risks, and how to obtain it in the United Kingdom.

Important safety information about Zumenon

Before reading further, note these essential safety points about Zumenon.

• Women with an intact uterus must take a progestogen alongside Zumenon to protect against endometrial hyperplasia and cancer.
• Oral HRT carries a small increased risk of blood clots (VTE) and stroke. Transdermal HRT (patches, gel) does not carry this VTE risk and is preferred for women with higher risk factors.
• Combined HRT (oestrogen plus progestogen) carries a small increased risk of breast cancer with use beyond 3 to 5 years.
• Use the lowest effective dose for the shortest duration needed. Review treatment annually.
• Report any abnormal vaginal bleeding to your prescriber promptly.

Understanding menopause and oestrogen deficiency

The ovaries are the primary source of estradiol (17-beta-estradiol) in premenopausal women, producing approximately 70 to 500 micrograms daily depending on the phase of the menstrual cycle.

Estradiol acts on oestrogen receptors (ER-alpha and ER-beta) in numerous target tissues: the reproductive tract, brain, cardiovascular system, bone, skin, and urogenital tissues.

Declining ovarian function during perimenopause and menopause leads to a progressive reduction in estradiol production, with postmenopausal levels typically below 50 pmol/L (compared with 200 to 1,500 pmol/L during the menstrual cycle).

Vasomotor symptoms (hot flushes and night sweats) are the hallmark of oestrogen deficiency.

They result from dysfunction of the thermoregulatory centre in the hypothalamus, where oestrogen withdrawal narrows the thermoneutral zone (the range of core body temperatures within which neither sweating nor shivering is triggered).

Even small fluctuations in core temperature trigger inappropriate heat-dissipation responses (peripheral vasodilation, sweating) or heat-conservation responses (shivering).

Neurokinin B (NKB) and kisspeptin neurones in the hypothalamic infundibular nucleus (KNDy neurones) are now recognised as key mediators of menopausal flushing, and their activity is modulated by oestrogen.

Urogenital atrophy results from oestrogen receptor loss in the vaginal epithelium, urethra, and bladder trigone, causing vaginal dryness, thinning and fragility of the vaginal mucosa, dyspareunia (pain during intercourse), urinary frequency, urgency, and recurrent urinary tract infections.

These symptoms typically worsen progressively after menopause and do not resolve spontaneously.

Accelerated bone loss (approximately 2 to 3% per year in the first 5 to 10 years after menopause) results from unopposed osteoclastic bone resorption in the absence of oestrogen's protective effect on bone metabolism.

This contributes to postmenopausal osteoporosis and fracture risk. Oestrogen deficiency also affects cardiovascular function (endothelial dysfunction, adverse lipid changes), cognitive function, mood, joint health, and skin integrity.

How Zumenon works

Zumenon delivers exogenous 17-beta-estradiol (body-identical oestrogen) to replace the estradiol no longer produced by the ovaries.

After oral administration, estradiol is absorbed from the gastrointestinal tract and undergoes extensive first-pass hepatic metabolism.

Approximately 95% of the oral dose is converted to estrone and estrone sulphate in the liver, with only approximately 5% reaching the systemic circulation as active estradiol.

Estrone sulphate acts as a circulating reservoir that can be reconverted to estradiol in target tissues by the enzyme steroid sulphatase and 17-beta-hydroxysteroid dehydrogenase.

The hepatic first-pass effect of oral estradiol is both a disadvantage and a consideration.

It results in a higher estrone-to-estradiol ratio (approximately 5:1) compared with the premenopausal ratio (approximately 1:1), meaning more oestrogen passes through the liver.

This hepatic exposure stimulates the synthesis of hepatic proteins including coagulation factors (fibrinogen, factor VII, factor X), sex hormone-binding globulin, angiotensinogen, and C-reactive protein.

These hepatic effects are responsible for the increased VTE risk associated with oral HRT.

Transdermal oestrogen (patches, gels) bypasses the liver, delivering estradiol directly into the systemic circulation with a physiological estrone-to-estradiol ratio and minimal hepatic protein stimulation, which is why transdermal delivery does not increase VTE risk.

Oral versus transdermal oestrogen

Both oral (Zumenon) and transdermal (Estradot patches, Oestrogel, Sandrena gel) oestrogen are effective for relieving menopausal symptoms. The choice depends on individual risk factors and preference.

Oral estradiol is convenient, widely available, and well-established.

Transdermal oestrogen bypasses hepatic first-pass metabolism, does not increase VTE or stroke risk, does not affect coagulation factors, triglycerides, or angiotensinogen, and is preferred for women with BMI above 30, age above 60, migraine, active gallbladder disease, previous VTE, or other thrombotic risk factors.

NICE guideline NG23 specifically recommends transdermal oestrogen for women at increased VTE risk.

Clinical evidence for HRT

The efficacy of HRT for menopausal symptom relief is supported by extensive randomised controlled trial evidence.

Oral estradiol 1 to 2 mg daily reduces hot flush frequency by 75 to 90% and severity by a similar magnitude, with improvement within 2 to 4 weeks and maximum effect at 8 to 12 weeks.

The Women's Health Initiative (WHI) study, the largest randomised HRT trial (over 27,000 women), provided long-term outcome data.

For women starting HRT within 10 years of menopause (the timing hypothesis), the overall benefit-risk balance is favourable, with reduced coronary heart disease risk, reduced fracture risk, and improved quality of life outweighing the small increases in VTE, stroke, and breast cancer risk.

The NICE menopause guideline NG23 (2015, updated 2019) recommends HRT as the first-line treatment for menopausal vasomotor symptoms.

It specifically advises that the baseline cardiovascular risk of women who start HRT under age 60 is low and the benefits outweigh the risks for most of these women.

The guideline recommends individualised risk-benefit assessment, use of the lowest effective dose, and annual review.

Dosage and administration

Start with Zumenon 1 mg daily. Increase to 2 mg daily if symptoms are not adequately controlled after 4 to 6 weeks. Use the lowest effective dose.

Take at the same time each day, with or without food. Women with an intact uterus must add a progestogen. Review annually.

Side effects of Zumenon

Common side effects

Breast tenderness, headache, nausea, abdominal bloating, leg cramps, and irregular bleeding or spotting (particularly in the first 3 to 6 months). These often settle with continued use.

Serious risks

VTE: approximately 1 to 3 additional cases per 1,000 women per year with oral HRT (eliminated with transdermal delivery).

Stroke: approximately 1 additional case per 1,000 women over 60 per year with oral HRT.

Breast cancer: small increase with combined HRT beyond 3 to 5 years; minimal or no increase with oestrogen-only HRT for up to 5 years.

Endometrial cancer: eliminated by adequate progestogen opposition. Gallbladder disease: increased risk with oral HRT. Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindicated in known or suspected breast cancer, oestrogen-dependent malignancy, undiagnosed vaginal bleeding, untreated endometrial hyperplasia, active or recent VTE or ATE, thrombophilic disorders, active liver disease, and porphyria.

Mandatory progestogen co-prescription for women with an intact uterus. Consider transdermal oestrogen for women at increased VTE risk. Investigate any unscheduled bleeding. Review annually.

Drug interactions with CYP3A4 inducers (reduced efficacy) and inhibitors (increased levels). Pregnancy: contraindicated.

Types of HRT regimen with Zumenon

Sequential combined HRT (for perimenopausal women)

Zumenon is taken daily continuously, with a progestogen added for 12 to 14 days per 28-day cycle (for example, days 15 to 28).

This regimen produces a predictable monthly withdrawal bleed during the progestogen-free days, similar to a menstrual period.

It is appropriate for women who are still having periods (even if irregular) or who have been postmenopausal for less than 12 months.

Common progestogen options for sequential use include norethisterone 5 mg for 12 days per cycle, medroxyprogesterone acetate 10 mg for 12 to 14 days per cycle, or dydrogesterone 10 mg for 14 days per cycle.

Continuous combined HRT (for postmenopausal women)

Zumenon is taken daily with a progestogen taken daily without a break. This regimen aims to produce a bleed-free state.

It is appropriate for women who have been postmenopausal for at least 12 months (no natural period for 12 months or more).

Common continuous progestogen options include norethisterone 1 mg daily, medroxyprogesterone acetate 2.5 to 5 mg daily, or a levonorgestrel-releasing intrauterine system (Mirena IUS, which provides endometrial protection for up to 5 years).

Irregular breakthrough bleeding may occur during the first 4 to 6 months of continuous combined therapy but usually settles.

Persistent bleeding beyond 6 months should be investigated (endometrial assessment).

Oestrogen-only HRT (for women after hysterectomy)

Women who have had a total hysterectomy (uterus removed) can take Zumenon daily without a progestogen, as there is no endometrium to protect.

This is the simplest HRT regimen and avoids progestogen-related side effects (breast tenderness, bloating, mood changes).

Women who have had a subtotal hysterectomy (cervix retained) may still have residual endometrial tissue and should discuss progestogen need with their prescriber.

How to get Zumenon in the UK

Zumenon is available on NHS prescription from your GP, menopause clinic, or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

HRT prepayment certificates and the NHS prescription prepayment certificate (PPC) can reduce costs for patients requiring multiple items.

Sources

• Zumenon 2 mg, Summary of Product Characteristics (EMC)
• Estradiol, British National Formulary (BNF)
• NICE NG23: Menopause: diagnosis and management
• Menopause, NICE CKS
• Hormone replacement therapy (HRT), NHS
• MHRA Yellow Card Scheme